View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 30, 2019updated 12 Jul 2022 12:23pm

Themis Bioscience and CEPI trial Lassa fever vaccine

Themis Bioscience and the Coalition for Epidemic Preparedness Innovations (CEPI) have commenced a Phase I clinical trial of Lassa fever vaccine candidate, MV-LASV.

Themis Bioscience and the Coalition for Epidemic Preparedness Innovations (CEPI) have commenced a Phase I clinical trial of Lassa fever vaccine candidate, MV-LASV.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

MV-LASV is based on Themis’ measles vector platform and findings licensed from Institut Pasteur. It is a live attenuated, recombinant, viral vectored vaccine formulated using the backbone of the measles Schwarz virus strain.

Under a global alliance, CEPI will fund the investigational vaccine’s development up to the Phase II completion. The Phase II trial will assess MV-LASV for its clinical safety and immunological data.

The company will also use the CEPI investment to build investigational stockpiles of the vaccine candidate. The stock will be trialled for clinical efficacy during outbreaks.

Themis Bioscience CEO Erich Tauber said: “Themis’ versatile technology platform and our ability to rapidly advance candidates into the clinic has been demonstrated previously through the discovery, development and production of a Phase III-ready vaccine candidate against Chikungunya, as well as our recently announced trial for a novel Zika vaccine.

“Our partnership with CEPI for Lassa fever further validates our capabilities and represents our combined commitment to tackle diseases that remain a public health threat globally.”

The Phase I trial will assess the safety, tolerability and immunogenicity of MV-LASV in 60 healthy adults. The assessments will be carried out following administration of two different dose levels.

Sponsored and led by Themis, the trial is taking place at the Centre for the Evaluation of Vaccination in Antwerp, Belgium.

CEPI Vaccine Development director Dr Melanie Saville said: “This first-in-human trial for Themis’ MV-LASV Lassa candidate is an important first step in its evaluation in the clinic and toward developing an effective vaccine, which will be available to at-risk populations during outbreaks of this deadly emerging infectious disease.”

Earlier this month, the company initiated a Phase I trial of a second-generation Zika vaccine in alliance with the ZIKAVAX consortium.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena